Finder's Pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Galmed Pharmaceuticals is a biotechnology business based in the US. Galmed Pharmaceuticals stocks (GLMD.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.93 – an increase of 9.52% over the previous week. Galmed Pharmaceuticals employs 19 staff and has a market cap (total outstanding stock value) of $12.1 million.
|Latest market close||$0.48|
|52-week range||$0.42 - $3.42|
|50-day moving average||$0.82|
|200-day moving average||$1.80|
|Wall St. target price||$4.13|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-1.19|
Note: The dollar amounts in the table below are in Canadian dollars.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|1 week (2022-06-17)||9.52%|
|1 month (2022-05-26)||-8.00%|
|3 months (2022-03-25)||-68.22%|
|6 months (2021-12-23)||-76.21%|
|1 year (2021-06-25)||-84.62%|
|2 years (2020-06-26)||-90.34%|
|3 years (2019-06-26)||6.46|
|5 years (2017-06-26)||6.02|
|Gross profit TTM||$0|
|Return on assets TTM||-41.18%|
|Return on equity TTM||-76.83%|
|Market capitalisation||$12.1 million|
TTM: trailing 12 months
We're not expecting Galmed Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Galmed Pharmaceuticals's shares have ranged in value from as little as $0.417 up to $3.42. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Galmed Pharmaceuticals's is 1.8253. This would suggest that Galmed Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Galmed Pharmaceuticals Ltd. , a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co. , Ltd.
Here are the best Canadian investment newsletters to help you boost your investment knowledge and grow your wealth.Read more…
Here are some investment ideas that could do well despite rising interest rates.Read more…
iGaming is now legal in Ontario. Find out which companies to keep an eye on with our list of 10 top online gaming stocks.Read more…
Everything we know about the Onfolio Holdings IPO plus information on how to buy in.
Steps to owning and managing ADN stock, with 24-hour and historical pricing before you buy.
Everything we know about the Mobilicom Limited IPO plus information on how to buy in.
Steps to owning and managing XLP stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing SCHH stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing IYK stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing VNQ stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing KIE stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing XLF stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing PXE stock, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.